In the Phase 2 CITYSCAPE trial, Tiragolumab, an anti-TIGIT antibody, demonstrated efficacy when combined with Atezolizumab, an anti-PD-L1, compared to Atezolizumab alone for the treatment of non-small cell lung carcinoma. In mouse models, inhibition of both the TIGIT and PD-1 pathways was shown to synergistically function to reinvigorate T cell [READ MORE]
I am a fan of musical theatre, and scientific meetings definitely have some aspect of performance – just imagine if speakers had to sing their talks? Perhaps a musical about cytokines could be the next hot thing to come to Broadway or the West End? Here are some proposed titles: [READ MORE]
Signals+ Editorial Board member, Maialen Sebastian, recently caught up with a 2023 ICIS-Pfizer Junior Investigator Award recipient, Iolanda Miceli for this interview. “I am concurrently completing my medical degree and scientific training at Monash University Melbourne. I never anticipated that my medical degree would morph into a PhD program as [READ MORE]
Students and Postdoctoral Researchers presenting novel and promising research may apply to receive a travel award to partially cover travel expenses. [READ MORE]
Have You Started Making Your Plan to Attend Cytokines 2024 / KAI 2024? Here’s Two More “Must Visit” Places in Seoul – and the latest list of symposia speakers confirmed by the Cytokine 2024 secretariat. [READ MORE]
Prof. Michael Gale, Jr. to head University of Minnesota’s Department of Microbiology and Immunology and become Director of the Institute on Infectious Diseases [READ MORE]
There have been many great (Cytokines) meetings for different reasons. But the standout for me was Hawaii 2022. It was the first face-to-face meeting post COVID lockdown era and Melbourne had one of the longest at 265 days!!! So this was the first time we had seen our international family in over 3 years! The excitement was palpable. It brought home all the values of our Science and this Society. [READ MORE]
My research investigates the function of innate immune receptors in gastric cancer and gastric inflammation.
Being on the ICIS council as a junior member for the past few years has been invaluable for my career. It’s provided insight into how international societies work, how conferences are organised and given me experience in activities outside of pure research.
After COVID travel restrictions, it’s been great to meet collaborators face to face, some for the first time. The 2023 meeting in Athens was great. There were great talks, good food and fun networking sessions! The music from Luke O’Neill’s band was a highlight. [READ MORE]
The International Cytokines & Interferon Society (ICIS) thrives on the invaluable contributions of individuals who generously devote their time and expertise to the Society. As we look to the future, we invite you, our members, to consider stepping into leadership roles that will drive the field of cytokine and interferon research to new heights. [READ MORE]
Mark Travis (Univ. of Manchester) is not an immunologist by training…. I did my BSc in Biochemistry and Genetics at Lancaster University, then a PhD in Protein Biochemistry at the University of Manchester, working on how integrins bind to ligands and signal. I then did my post-doc at UCSF, where I started working on integrins that bind and activate the cytokine TGF-beta. I made a conditional knockout mouse while I was there that got an intestinal inflammation phenotype, so I quickly morphed into becoming a mucosal immunologist…. which I have been ever since. [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
